Cervical Dystonia Market to Observe Stupendous Growth During the Forecast Period (2032) – Estimates DelveInsight | AEON Biopharma (ABP-450), Revance Therapeutics, Addex Therapeutics, Medytox, Ipsen
DelveInsight’s “Cervical Dystonia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Cervical Dystonia Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Cervical Dystonia market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Cervical Dystonia: An Overview
Cervical Dystonia (CD) is a chronic neurological disorder characterized by involuntary contractions of the cervical musculature that lead to abnormal movements and postures of the head. In some cases, these abnormal contractions may be sustained or continuous; in others, they may be present as spasms that can resemble tremors.
The pattern of neck muscle involvement in patients with CD is variable, leading to clinically heterogeneous directional presentations, such as torticollis, laterocollis, retrocollis, or anterocollis.
The chance that dystonia will affect multiple body parts is generally linked to the age of onset. The younger one is at onset, the greater the chance that symptoms will spread. Conversely, the older one is at onset, the more likely it is that the disorder will remain more moderate.
According to the NORD, cervical dystonia affects women approximately twice as often as men. It is the most common form of focal dystonia in an office setting.
Cervical Dystonia Market Key Facts
-
The prevalence of Cervical Dystonia in the United States is estimated to be around 400 per 100,000, and a recently published meta-analysis of primary dystonia suggested an overall CD prevalence of about 50 per million. (Jankovic J et al 2007, Steeves TD, 2012).
-
In Southern Italy, cervical dystonia was commonest in patients aged 35–54 years, with a prevalence of 44.8 per 1,000,000 (Anna Maria Papantonio et al., 2009).
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Cervical Dystonia market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Cervical Dystonia market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Cervical Dystonia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.
Cervical Dystonia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cervical Dystonia market or expected to get launched during the study period. The analysis covers Cervical Dystonia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Cervical Dystonia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Key Developments in the Cervical Dystonia Therapeutics Market
On September 23, 2022, AEON Biopharma announced positive topline results from its Phase 2 clinical study of ABP-450 for the treatment of cervical dystonia (CD). ABP-450 contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
Learn How Cervical Dystonia Market Will Evolve by 2032:-
https://www.delveinsight.com/sample-request/cervical-dystonia-market
Some of the Key companies in the Cervical Dystonia Market include:
-
Revance Therapeutics
-
Addex Therapeutics
-
Medytox
-
Ipsen
-
Allergan
And many others.
Cervical Dystonia Therapies Covered in the Report Include:
-
Botox (OnabotulinumtoxinA
-
RT002
-
Dipraglurant-ER
And many others.
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More @
https://www.delveinsight.com/sample-request/cervical-dystonia-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Cervical Dystonia Competitive Intelligence Analysis
4. Cervical Dystonia Market Overview at a Glance
5. Cervical Dystonia Disease Background and Overview
6. Cervical Dystonia Patient Journey
7. Cervical Dystonia Epidemiology and Patient Population (In US, EU5, and Japan)
8. Cervical Dystonia Treatment Algorithm, Current Treatment, and Medical Practices
9. Cervical Dystonia Unmet Needs
10. Key Endpoints of Cervical Dystonia Treatment
11. Cervical Dystonia Marketed Products
12. Cervical Dystonia Emerging Drugs and Latest Therapeutic Advances
13. Cervical Dystonia Seven Major Market Analysis
14. Attribute Analysis
15. Cervical Dystonia Market Outlook (In US, EU5, and Japan)
16. Cervical Dystonia Access and Reimbursement Overview
17. KOL Views on the Cervical Dystonia Market
18. Cervical Dystonia Market Drivers
19. Cervical Dystonia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
https://www.delveinsight.com/sample-request/cervical-dystonia-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
“Usher Syndrome Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Usher Syndrome Market size, share, and trends in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
 – Estimates DelveInsight | AEON Biopharma (ABP-450), Revance Therapeutics, Addex Therapeutics, Medytox, Ipsen){kind=link}